VINACHEM

NEW YORK (ICIS)--The global chemical mergers and acquisitions (M&A) market is set to get an extra kick in 2014 as chemical companies become more aggressive on transformations, shedding non-core assets to focus on key growth areas. The financing market for deals is also expected to remain strong, along with buyer interest from both strategic and financial players.

“Barring some major jolt to the global economic or financial situation, we expect a continuation of a healthy chemical M&A market, with some increase in the number of large deals. The only area where volume will continue to be subdued is in Europe due to weak industry conditions,” said Peter Young, president of investment bank Young & Partners.

“In the second half of 2013, everyone threw their non-core assets onto the selling block, as the pendulum swung definitively into being a seller’s market,” said Telly Zachariades, partner at investment bank The Valence Group.

“Valuations are relatively high, but there is still an absence of organic growth. M&A is one way to jump-start growth,” he added.

A number of chemical companies such as Dow Chemical, DuPont, Ashland, LANXESS, Chemtura and Rockwood Holdings have announced portfolio restructurings.

“Yet not all of those restructuring announcements will result in M&A,” Young said. “A good example is DuPont, where it ended up deciding to spin off its performance chemicals business to shareholders rather than sell to a strategic or financial buyer.”

In October 2013, US-based DuPont announced the planned spinoff of its performance chemicals segment, which includes its titanium dioxide (TiO2) and chemicals and fluoroproducts businesses. These assets had sales of around $7bn in 2012.

The spinoff to existing shareholders would take place in around 18 months from the announcement. DuPont had been evaluating all strategic options for the businesses, including a sale.

Earlier in July 2013, activist investor Nelson Peltz, who runs Trian Partners, announced he was making a major investment in DuPont. By August he reportedly had a 2.2% stake in the company.

“Some of this activity has been prompted by shareholder activist actions, but many of those have not resulted in a sale of all or part of the companies targeted,” noted Young.

On the buy side, chemical companies are still interested in acquisitions as they seek to boost growth in core businesses.

“In the US there is a lot of interest in M&A activity to refocus and grow in core businesses. Some companies have been rewarded by the market and are emboldened to do transactions,” said Leland Harrs, managing director and head of chemicals at investment bank Houlihan Lokey.

One prominent example of a company proactively making acquisitions to bolster core businesses and divest non-core asset sales is US-based coatings firm PPG Industries.

Following a series of moves, including the merger of its chlor-alkali business with Georgia Gulf to create integrated polyvinyl chloride (PVC) producer Axiall, and the acquisition of AkzoNobel’s North American architectural coatings business, PPG has 90% of its pro forma sales in the core coatings business.

“There is more of an imperative to focus on core businesses. Those with non-core assets are feeling more pressure to divest,” Harrs said.

The more sanguine outlook based on portfolio restructuring follows what many bankers considered a weaker-than-expected M&A market in 2013.

“There are a lot of larger transactions slated to take place now, but in the past, many divestitures revolved around smaller sub-$200m deals, and we haven’t seen a lot of those,” said Mario Toukan, managing director and head of the chemicals investment banking at KeyBanc Capital Markets.

“There was a meaningful increase in both the number and dollar volume of chemical M&A deals completed in 2013 compared to 2012’s trough levels – on the order of 25-30%,” said Young of Young & Partners. “However, the average deal size is still relatively moderate. There are just fewer large deals than what we saw in 2011.”

Portfolio restructuring
However, larger companies are certainly accelerating transformations by putting assets up for sale, partnerships or initial public offerings (IPOs).

US-based Dow Chemical is carving out its chlorine and derivatives businesses – assets with annual sales of around $5bn – for future transactions in 12-24 months from December 2013. This includes its US chlor-alkali, global epoxy resins and global chlorinated organics businesses.

“For Dow, there is a higher probability that these assets will be sold, but it is clear that Dow will not sell any business unless it gets the right price. The probability of a spinoff is not zero,” said Young of Young & Partners.

Dow pulled the sale of its plastic additives business in September 2013 because the bids were too low.

The global TiO2 sector is poised to see a major shift in ownership with US-based Huntsman also planning an IPO of its combined TiO2, inorganic pigments and functional additives businesses, following the completion of its acquisition of Rockwood Holdings’ specialty TiO2 business for $1.1bn in cash and $225m in assumed pension liabilities. The acquisition is expected to be completed in the first half of 2014, and the IPO within two years of the close. The combined assets have sales of around $3bn.

Huntsman is also restructuring its surfactants business in Europe. In October 2013 it said it was “in discussions with potential partners for certain facilities”.

Also in October, US-based Chemtura announced it is exploring the sale of its agricultural chemicals business after signing a deal that month to sell its consumer products division to Canada-based KIK Custom Products for $315m in cash.

Chemtura’s agrochemicals business generated sales of $435m and earnings before interest, tax, depreciation and amortisation (EBITDA) of $89m in the 12 months prior to 30 June 2013.

While recognising the strength of the agrochemicals business and its growth prospects, Chemtura CEO Craig Rogerson said that after receiving unsolicited interest, the board decided that “this is the right time to invite and evaluate offers for the business”.

“It’s not a bad business, but management is thinking, ‘What better time than now to unload?’” said one source in the financial community.

Germany-based LANXESS has identified several businesses with combined annual sales of around €500m ($687m) and €30m in EBITDA it deems non-core, and for which it is evaluating strategic options. This includes the Perlon-Monofil polyamide and polyester monofilaments unit of its high performance materials business, the accelerators and antioxidants business of its rubber chemicals division, and the nitrile butadiene rubber line of its high performance elastomers business.

While there could be a higher amount of large chemical deals – those $1bn and above - in 2014, the odds of a major rebound are slim, said Young of Young & Partners.

“A scenario by which people are going to become very confident and pursue many large deals is highly unlikely,” Young said. “You would have to see real signs of a major improvement in Europe to get a real boost in confidence. There is also the upcoming debt ceiling in the US along with a huge overall fear of [the US Federal Reserve] tapering.”

Activist investors
The acceleration of portfolio restructuring among chemical companies is not coming out of nowhere. The flurry of activist investor activity in the sector is a major factor in driving such activity.

“2014 will be a better year, partly because there is so much corporate divestiture activity in the pipeline. And these portfolio realignments are partly being driven by activist activity,” said Chris Cerimele, managing director at investment bank Grace Matthews.

“Activist investors are pushing boards to evaluate their portfolios,” he added.

In the US, activist investors have taken stakes in DuPont, Air Products, Ashland, Ferro, American Pacific and Calgon Carbon.

“Managements are very conscious of the potential for activists getting involved if they are not proactive stewards of their portfolios,” said Houlihan Lokey’s Harrs. “There has been the rise of targeted hedge funds willing to take these positions, whereas private equity firms typically cannot do hostile transactions, as indicated in their charters.”

Yet investors can be creative. One hybrid private equity/activist investor entity founded by Jeffry Quinn, former CEO of US-based chemical company Solutia, along with other Solutia executives, is Quinpario Partners.

The group says it “specialises in transforming underperforming and underfunded businesses to create shareholder value”. It has taken stakes in US chemical companies Ferro and Zoltek, pushing for changes. Carbon fibre producer Zoltek is being sold to Japan-based Toray.

In August 2013, Quinpario Partners completed a $172.5m IPO of Quinpario Acquisition Corp, a “blank-check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses”.

Private equity interest
There is no lack of interest among private equity firms, as they continue to scour the market for deals, often in connection with former chemical executives.

Private equity firms led by or with ties to prominent former chemical executives include New Mountain Capital with former Rohm and Haas CEO Raj Gupta; Arsenal Capital with John Televantos, former president of the Aqualon division of Hercules and CEO of Foamex; SK Capital with Barry Siadat, former chief growth officer of AlliedSignal; and Lion Chemical Capital, which owns styrene butadiene rubber (SBR) and ethylenepropylene diene monomer (EPDM) producer Lion Copolymer.

“The more successful private equity firms in chemicals tend to have former executives on staff. The chemical sector is not as intuitive a business as other industries, and also a bit of a club,” said Cerimele of Grace Matthews.

Oil and gas, water
Hot sectors of focus for private equity, along with other buyers, include oilfield chemicals and water treatment, along with chemical distribution.

There is consensus among investment bankers that oil and gas chemicals is one of the hottest sectors, attracting interest from both corporate and private equity buyers.

“It is one of the few areas where private owners are selling. There are half a dozen deals out there,” said KeyBanc’s Toukan. “A number of these companies were just start-ups a few years ago, but the growth path is phenomenal.”

“There is a high degree of interest in acquiring oilfield chemical assets that will fuel good activity as noted by the recent announcements of the acquisition of Chemlogics by Solvay, Bachman Services by Innospec and Permian Mud Service [Champion Technologies] earlier in 2013 by Ecolab,” said Allan Benton, vice chairman and the head of the chemical practice at investment bank Scott-Macon.

Belgium-based Solvay bought US-based oil and gas chemicals company Chemlogics for $1.35bn in October 2013. US-based Ecolab closed its acquisition of Champion in April 2013 for around $2.3bn, including the assumption of debt.

In December 2013, Canada-based Chemtrade Logistics agreed to buy US-based General Chemical for $860m in cash. General Chemical operates in water treatment chemicals, sulphuric acid and specialty chemicals. The purchase price represents a multiple of 7.8 times last 12 months EBITDA.

In December 2013, private equity firm Arsenal Capital Partners announced the acquisition of Flowchem, a producer of chemicals to improve pipeline flow in onshore and offshore pipelines.

Financing market robust
Meanwhile, the financing market is robust with relatively low interest rates and availability.

“Debt markets are positive, so there are tailwinds to support an increase in M&A activity. Plus, company balance sheets are very strong and getting stronger. Many companies have not acted but are poised to be more acquisitive,” said Houlihan Lokey’s Harrs.

“The Great Recession is behind us, and even Europe is coming out of the woods. This will spur interest in doing deals,” he added.

“So far, financing markets are still very strong, encouraging private equity activity,” said Grace Matthews’ Cerimele.

However, these conditions won’t last forever, one banker warns.

“Right now there is still a plentiful supply of cheap money available, but one day this will come to an end,” said The Valence Group’s Zachariades. “And as economic activity rises, the alternative to M&A becomes more attractive. Companies may want to invest more in organic growth.”

Small, family-owned assets
One aspect of the chemical M&A market that has not taken off is sales of small, family-owned enterprises, said KeyBanc’s Toukan.

In 2009, 80% of all chemical M&A volume consisted of deals $100m and below in value. In 2013, the figure was around 50%, the banker noted.

“The financing market has been remarkable, with the high yield market particularly strong, but smaller businesses are less impacted by this. They just need a few years of steady performance under their belts prior to sale, and it’s been a mixed performance for many in the past 2-3 years,” said Toukan.

Scott-Macon’s Benton sees a stronger outlook for 2014 deals in the mid-market.

“With high valuations and low interest rates, it is a good environment if anyone wants to sell. People that have owned businesses privately for years may need to sell for estate reasons,” said Benton.

LBO market and valuations
Leveraged buyouts (LBO) by private equity firms have also been few and far between in the chemical sector in 2013, with financial buyers accounting for around 13% of the number of chemical deals in 2013 versus around 20% in 2012. The historical average has been about 10%, said Toukan.

“Even though the financing market has been red hot, there have not been that many LBOs,” he noted.

Part of that has to do with the relatively high public and also M&A valuations. “Whatever assets on the market are selling for record levels, and you can see that reflected in public company valuations which are around 10.5 times EV/EBITDA [enterprise value/EBITDA],” said Toukan.

For the last 45 publicly announced chemical transactions to mid-December 2013, strategic buyers paid 9.2 times EBITDA on average versus 7.7 times for financial sponsors, according to Toukan’s analysis.